371 related articles for article (PubMed ID: 10589362)
81. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.
Sidiropoulos P; Bertsias G; Kritikos HD; Kouroumali H; Voudouris K; Boumpas DT
Ann Rheum Dis; 2004 Feb; 63(2):144-8. PubMed ID: 14722202
[TBL] [Abstract][Full Text] [Related]
82. [A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation].
Dejaco C; Duftner C; Wipfler E; Schirmer M
Wien Med Wochenschr; 2009; 159(3-4):70-5. PubMed ID: 19247593
[TBL] [Abstract][Full Text] [Related]
83. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy.
Boers M;
Arthritis Rheum; 2001 Nov; 44(11):2703-4. PubMed ID: 11710727
[No Abstract] [Full Text] [Related]
84. Infliximab for the treatment of early rheumatoid arthritis.
Geletka RC; St Clair EW
Expert Opin Biol Ther; 2005 Mar; 5(3):405-17. PubMed ID: 15833077
[TBL] [Abstract][Full Text] [Related]
85. [Association of short-term efficacy for infliximab in rheumatoid arthritis with plasma concentration and anti-drug antibody].
Song M; Li F; Xie X; Chen J; Tang M; Tian J; Du J; Ge Y; Li S; Xu S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Sep; 43(9):982-986. PubMed ID: 30333289
[TBL] [Abstract][Full Text] [Related]
86. Role of infliximab in the treatment of early rheumatoid arthritis.
Keystone EC; Haraoui B; Bykerk VP
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S200-2. PubMed ID: 14969078
[TBL] [Abstract][Full Text] [Related]
87. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.
Gonzalez-Gay MA; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
Clin Exp Rheumatol; 2006; 24(1):83-6. PubMed ID: 16539824
[TBL] [Abstract][Full Text] [Related]
88. Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.
Cobo Ibáñez T; Yehia Tayel M; Balsa Criado A; Hernández Sanz A; Martín Mola E
Rheumatology (Oxford); 2005 Nov; 44(11):1467-8. PubMed ID: 16174647
[No Abstract] [Full Text] [Related]
89. [Pharmacological profile of anti-human TNF alpha monoclonal antibody, infliximab (Remicade)].
Sugita T
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):57-64. PubMed ID: 12617039
[TBL] [Abstract][Full Text] [Related]
90. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-α.
Benedek TG
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S3-8. PubMed ID: 21044425
[TBL] [Abstract][Full Text] [Related]
91. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
Saleem B; Mackie S; Quinn M; Nizam S; Hensor E; Jarrett S; Conaghan PG; Emery P
Ann Rheum Dis; 2008 Aug; 67(8):1178-80. PubMed ID: 18234715
[TBL] [Abstract][Full Text] [Related]
92. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
Siddiqui MA; Scott LJ
Drugs; 2005; 65(15):2179-208. PubMed ID: 16225377
[TBL] [Abstract][Full Text] [Related]
93. Combination treatment of rheumatoid arthritis with cyclosporine and methotrexate.
Stein CM; Pincus T
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S47-52. PubMed ID: 10589357
[TBL] [Abstract][Full Text] [Related]
94. Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients.
Coulthard LR; Geiler J; Mathews RJ; Church LD; Dickie LJ; Cooper DL; Wong C; Savic S; Bryer D; Buch MH; Emery P; Morgan AW; McDermott MF
Clin Exp Immunol; 2012 Oct; 170(1):36-46. PubMed ID: 22943199
[TBL] [Abstract][Full Text] [Related]
95. Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis.
Hwang YG; Moreland LW
Curr Rheumatol Rep; 2014 May; 16(5):417. PubMed ID: 24619653
[TBL] [Abstract][Full Text] [Related]
96. Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.
Nordström DC; Konttinen L; Korpela M; Tiippana-Kinnunen T; Eklund K; Forsberg S; Ilva K; Kaipiainen-Seppänen O; Malmi T; Ylä-Kerttula T; Honkanen V
Rheumatol Int; 2006 Jun; 26(8):741-8. PubMed ID: 16205925
[TBL] [Abstract][Full Text] [Related]
97. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study.
Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Aranda R; Becker JC; Nys M; le Bars M; Reed DM; Poncet C; Dougados M
Ann Rheum Dis; 2011 Nov; 70(11):2003-7. PubMed ID: 21914628
[TBL] [Abstract][Full Text] [Related]
98. Infliximab: a new treatment for rheumatoid arthritis.
Emery P
Hosp Med; 2001 Mar; 62(3):150-2. PubMed ID: 11291464
[TBL] [Abstract][Full Text] [Related]
99. The other side of TNF-targeted therapy of patients with rheumatoid arthritis.
Abe T; Takeuchi T
Curr Rheumatol Rep; 2001 Feb; 3(1):1-2. PubMed ID: 11177764
[No Abstract] [Full Text] [Related]
100. Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab.
Covelli M; Scioscia C; Iannone F; Lapadula G
Clin Exp Rheumatol; 2005; 23(2):145-51. PubMed ID: 15895882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
